1.A study on changes of coagulation inhibitors and fibrinolysis inhibitors in patients with liver cirrhosis and hepatoma.
Chan Jeoung PARK ; Han Ik CHO ; Sang In KIM
Journal of Korean Medical Science 1991;6(1):1-6
The authors conducted an investigation focusing mainly on the activities of the inhibitory factors of the coagulation and fibrinolysis processes in 35 normal adults and 72 liver cirrhosis and/or hepatoma patients. The activities of antithrombin III, protein C, and alpha 2-plasmin inhibitor were reduced to less than 50% in patients with decreased hepatic synthetic function while lupus anticoagulant was detected in more than 50% of patients with decreased hepatic synthetic function. Hemostatic abnormalities in advanced lived diseases may be caused partly by a decrease of coagulation and fibrinolysis inhibitors and the presence of lupus anticoagulant.
Adult
;
Antifibrinolytic Agents/blood
;
Blood Coagulation Factors/antagonists & inhibitors/immunology/metabolism
;
Carcinoma, Hepatocellular/*blood
;
Hemostasis
;
Humans
;
Liver Cirrhosis/*blood
;
Liver Neoplasms/*blood
;
Lupus Coagulation Inhibitor
2.Lupus anticoagulant: two cases report and literature review.
Yang LI ; Ming' en LYU ; Feng XUE ; Wenjie LIU ; Yating HAO ; Yue GUAN ; Boyang SUN ; Cuicui LYU ; Xueping GU ; Rongfeng FU ; Yueting HUANG ; Wei LIU ; Yunfei CHEN ; Xiaofan LIU ; Lei ZHANG ; Renchi YANG
Chinese Journal of Hematology 2016;37(2):130-133
OBJECTIVETo deepen the understanding of clinical manifestations and treatment of patients with positive lupus anticoagulant (LAC).
METHODSThe clinical data of 2 patients were analyzed and related literature were reviewed.
RESULTSCase 1, a 31-year-old female, diagnosed as lupus anticoagulant positive, secondary to undifferentiated connective tissue disease, was presented with menorrhagia and thrombocytopenia. Anti-nuclear antibody (ANA) was positive 1:1000 (homogeneous type) with anti-double stranded DNA positive, and dRVVT LA1/LA2 was 3.4. Coagulation function was alleviated after treatment with glucocorticoid and total glucosides of paeony. Case 2, a 59-year-old female was presented with gingival bleeding, hematuria with the level of F II:C 13%. dRVVT LA1/LA2 was 2.0. Anti-nuclear antibody (ANA) was positive 1:1000 (type of cytoplasmic granule), anti-double stranded DNA was positive. The patient was diagnosed as hypoprothrombinemia-lupus anticoagulant syndrome (LAHS) and acquired coagulation factor deficiency. The signs of hemorrhage were alleviated after treatment with methylprednisolone 40 mg/day and cyclophosphamide, while the level of F II:C was below normal.
CONCLUSIONSymptoms of patients with positive LAC are variable. The diagnosis relies on history of disease and laboratory test. Currently, there is no standardized treatment. Cases of LAHS should be thoroughly investigated for any known causes and related disorder.
Adult ; Blood Coagulation ; Cyclophosphamide ; therapeutic use ; Female ; Glucocorticoids ; therapeutic use ; Hematologic Tests ; Hemorrhage ; Humans ; Hypoprothrombinemias ; diagnosis ; Lupus Coagulation Inhibitor ; blood ; Methylprednisolone ; therapeutic use ; Middle Aged
3.The Value of Preoperative Coagulation Screening in Children Undergoing Surgery.
Korean Journal of Hematology 2008;43(2):98-105
BACKGROUND: To evaluate the usefulness of preoperative screening for coagulation disorders in children who have undergone surgery. METHODS: From January 2003 to December 2005, we prospectively evaluated laboratory and bleeding histories in 1,911 children between the ages of one year and 15 years. All of the patients had preoperative coagulation screening with a measurement of complete blood count, prothrombin time and activated partial thromboplastin time. The sensitivity, specificity and positive and negative predictive values following a preoperative coagulation-screening test were evaluated by a comparison of the type of surgery and bleeding complications that occurred during and after surgery. RESULTS: There were no patients with previously proven coagulopathies or suspicious medical histories. Among the 1,911 cases, a subset of 22 patients had persistent abnormalities detected after laboratory testing. In two of the 22 patients, lupus anticoagulant was detected and in one of the 22 patients, a factor VIII deficiency was discovered. There were 46 patients that had postoperative bleeding and required hospitalization extension or readmission for stanching. Among the 46 patients, 44 patients demonstrated normal coagulation after testing and two patients demonstrated abnormal coagulation after testing. Following a preoperative coagulation-screening test, a low sensitivity (0.04) and positive predictive value (0.09) were determined. CONCLUSION: For the prediction of perioperative bleeding, the use of a coagulation-screeningtest showed a very low positive predictive value. Many false positive laboratory tests coupled with the relative rarity of inherited and acquired coagulopathies raises doubt about the overall value of routine preoperative coagulation screening in children.
Blood Cell Count
;
Blood Coagulation Tests
;
Child
;
Hemophilia A
;
Hemorrhage
;
Hospitalization
;
Humans
;
Lupus Coagulation Inhibitor
;
Mass Screening
;
Partial Thromboplastin Time
;
Prospective Studies
;
Prothrombin Time
;
Sensitivity and Specificity
4.Recurrent epistaxis with coagulation disorders in a boy aged 2 years.
Jia-Zhuo LI ; Xin TIAN ; Chu-Shu LIAO ; Xiang-Ling HE ; Cheng-Guang ZHU
Chinese Journal of Contemporary Pediatrics 2022;24(7):817-820
A boy, aged 2 years and 5 months, had recurrent epistaxis, and the coagulation function examination showed that activated partial thromboplastin time (APTT) was significantly prolonged. Further laboratory examinations showed that the prolonged APTT was not immediately corrected in the APTT correction test, with positive lupus anticoagulant and low prothrombin activity. The boy was diagnosed with hypoprothrombinemia-lupus anticoagulant syndrome. The condition was improved after treatment with glucocorticoid, immunoglobulin, and vitamin K1. The boy has been followed up for 6 months, and no epistaxis was observed. Prothrombin activity returned to normal, and lupus anticoagulant remained positive. This is a relatively rare disease, and for patients with bleeding symptoms and coagulation disorders, it is recommended to perform the tests such as APTT correction test, lupus anticoagulant testing, and coagulation factor dilution test, which can improve the detection rate of this disease, so as to achieve early diagnosis, provide rational treatment in the early stage, and improve the prognosis.
Antiphospholipid Syndrome/diagnosis*
;
Blood Coagulation Disorders
;
Child, Preschool
;
Epistaxis/etiology*
;
Humans
;
Hypoprothrombinemias/diagnosis*
;
Lupus Coagulation Inhibitor
;
Male
;
Partial Thromboplastin Time
;
Prothrombin
5.Prevalence and Clinical Associations of Lupus Anticoagulant, Anticardiolipin Antibodies, and Anti-beta2-glycoprotein I Antibodies in Patients with Systemic Lupus Erythematosus.
Kwang Sook WOO ; Kyung Eun KIM ; Jeong Man KIM ; Jin Yeong HAN ; Won Tae CHUNG ; Kyeong Hee KIM
The Korean Journal of Laboratory Medicine 2010;30(1):38-44
BACKGROUND: The presence of antiphospholipid antibodies (aPLs) is associated with the clinical features of antiphospholipid syndrome (APS), which comprises venous and arterial thrombosis and pregnancy loss, and systemic lupus erythematosus (SLE). The prevalence of aPLs has been reported to be different in patient populations affected by either of these conditions. We performed a retrospective study to evaluate the prevalence and clinical associations of aPLs, including lupus anticoagulant (LAC), anticardiolipin (aCL), and anti-beta2-glycoprotein I antibodies (anti-beta2-GPI) in a cohort of Korean patients with SLE. METHODS: This study included samples from 88 SLE patients for whom aPL testing had been advised between June 2006 and July 2009 at the Dong-A University Hospital. Serum and plasma samples were tested for LAC, aCL (IgG, IgM), and anti-beta2-GPI (IgG, IgM) antibodies. Clinical data from patients were obtained from a review of medical records. RESULTS: LAC was the most common (34.1% of total patients, 30/88) antibody, followed by IgM aCL (31.8%, 28/88), IgG aCL (18.2%, 16/88), and IgM and IgG anti-beta2-GPI (both 5.7%, 5/88 each). Positivity for LAC was strongly associated with venous/arterial thrombosis (P=0.002). CONCLUSIONS: LAC was the most common antibody detected in Korean SLE patients and is shown to have a significant association with the presence of venous/arterial thrombosis. The measurement of LAC may be clinically useful in identifying patients with SLE who are at a high risk for venous/arterial thrombosis.
Adolescent
;
Adult
;
Antibodies, Anticardiolipin/*blood
;
Antibodies, Antiphospholipid/*blood
;
Cohort Studies
;
Female
;
Humans
;
Immunoglobulin G/blood
;
Immunoglobulin M/blood
;
Lupus Coagulation Inhibitor/*blood
;
Lupus Erythematosus, Systemic/epidemiology/*immunology
;
Male
;
Middle Aged
;
Pregnancy
;
Prevalence
;
Retrospective Studies
;
Risk Factors
;
Venous Thrombosis/epidemiology/immunology
6.The Clinical Significance of Antiphospholipid Antibodies in Korean Children with Henoch-Schonlein Purpura.
Eun Jung PARK ; Ji Young BAEK ; Jae Il SHIN ; Jae Seung LEE ; Hyon Suk KIM
Journal of the Korean Society of Pediatric Nephrology 2009;13(2):146-152
PURPOSE: We performed this study to evaluate the incidence and clinical significance of antiphospholipid antibodies (aPL Ab) in Korean children with Henoch-Schonlein purpura (HSP). METHODS: The medical records of 62 patients (31 boys and 31 girls) aged 6.0+/-3.1 (1-16) years with a clinical diagnosis of HSP based on the EULAR/PReS criteria were reviewed retrospectively. From the years 2007 to 2009, the sera from children with acute HSP were tested for aPL Ab such as LA, anti-cardiolipin antibody and anti-beta2 glycoprotein I antibody. RESULTS: LA was positive in 18 (29%) of the 62 patients with HSP and We divided the patients into the two groups LA positive group (N=18) and LA negative group (N=44). There were no significant differences between the two groups with regard to abdominal pain, arthralgia and renal involvement, but LA positive group had significantly higher C-reactive protein (4.3+/-7.2 mg/dL vs. 1.3+/-1.8 mg/dL, P=0.035), erythrocyte sedimentation rate (37.5+/-26.2 mm/hr vs. 25.1+/-22.6 mm/hr, P= 0.039), IgM (148.1+/-48.4 mg/dL vs. 114.9+/-41.5 mg/dL, P=0.024), C3 (143.1+/-21.9 mg/dL vs. 129.7+/-24.5 mg/dL, P=0.048) and C4 levels (30.9+/-6.3 mg/dL vs. 24.9+/-7.8 mg/dL, P=0.002) compared with LA negative group. CONCLUSION: We found that the incidence of positive aPL Ab tests was relatively higher in Korean children with HSP and the presence of aPL Ab was associated with acute inflammatory process of HSP. These results suggest that the aPL Ab are involved in the pathogenesis of HSP in children.
Abdominal Pain
;
Aged
;
Antibodies, Antiphospholipid
;
Arthralgia
;
Blood Sedimentation
;
C-Reactive Protein
;
Child
;
Glycoproteins
;
Humans
;
Immunoglobulin M
;
Incidence
;
Lupus Coagulation Inhibitor
;
Medical Records
;
Purpura, Schoenlein-Henoch
;
Retrospective Studies
7.A Case of Secondary Antiphospholipid Antibody Syndrome with Thyroid Cancer.
Seung Hun KANG ; Sung Jae CHOI ; Young Ho LEE ; Jong Dae JI ; Gwan Gyu SONG
Journal of Rheumatic Diseases 2011;18(1):46-49
Antiphospholipid antibody syndrome (APS) is defined as the presence of lupus anticoagulant antibody or anticardiolipin antibody with vascular thrombosis or pregnancy complications. APS can be associated with autoimmune disease or infectious disease. APS has also been reported in conjunction with variety of solid and hematologic malignancies. There were some reports on APS which were accompanied by hematologic malignancy, but there was no report with solid malignancy in Korea. We experienced one case of secondary APS, which was diagnosed during pre-operative evaluation of thyroid cancer. This patient had prolonged aPTT (activate partial thromboplastin time) and decreased coagulation factors which were regarded as hemophilia at first. Although the precise mechanism of the relationship between APS and cancer has not been proven thoroughly, APS can be accompanied by various malignancies. So proper screening and early detection of malignancies in APS patients are recommended.
Antibodies, Anticardiolipin
;
Antibodies, Antiphospholipid
;
Antiphospholipid Syndrome
;
Autoimmune Diseases
;
Blood Coagulation Factors
;
Communicable Diseases
;
Hematologic Neoplasms
;
Hemophilia A
;
Humans
;
Korea
;
Lupus Coagulation Inhibitor
;
Mass Screening
;
Pregnancy Complications
;
Thromboplastin
;
Thrombosis
;
Thyroid Gland
;
Thyroid Neoplasms
8.Anticardiolipin Antibody (ACA) and Lupus Anticoagulant (LA): Association with Vascular Access Occlusion in Hemodialysis (HD) Patients.
Duk Hee KANG ; Seung Ki RYU ; Sung Nam KIM ; Kyun Il YOON ; Yoon Ha LEE
Korean Journal of Medicine 1997;53(5):661-670
OBJECTIVES: Anticardiolipin antibody (ACA) and lupus anticoagulant (LA) are acquired antiphospholipid antibodies (APAs), which are regarded as important risk factors far vascular thrombosis and recurrent fetal loss. Although the clinical relevance of APAs in dialysis patients is uncertain, recent studies have suggested that APAs are involved in bioincompatibility and thrombogenic complications in hemadialysis (HD) patients. METHOD: We performed a cross sectional study of ACA and LA in 50 stable HD patients and their 68 vascular accesses (52 native arteriovenous fistulae and 16 synthetic arterovenous grafts), with the analysis of factors associated with the presence of APAs and the retrospective evaluation of vascular access occlusion (VAO). LA was assessed by platelet neutralization method whereas IgG-ACA was measured by a solid phase ELISA. Values higher than 23GPLU/ml (IgG phospholipid units) were considered to be positive for IgG-ACA and positive values for LA was more than 8 seconds in prolongation of the clotting time with human platelet lysate. Vascular access survival was assessed by Kaplan- Meier method, RESULTS: The mean age of the subject (M:F 21:29) was 46 years and the mean duration of hemodialysis was 49 months. The frequency of VAO in entire subjects was 0.45+/-0.98 episodes/patient year. The median value of IgG-ACA was 16.0 GPLU/ml with a distribution from 2.7 to 46.1GPLU/ ml. The median titer of I.A was 4.5 (3.1-45.6) seconds. Fourteen patients (28%) were found to have at least one episode of VAO. In spite of comparable clinical and biochemical data according to the presence of VAO, the titers of IgG-ACA (13.6+/-7.7 vs, 20.3+/-8.7GPLIJ/ml, P<0.05) and LA (4.5+/-2.9 vs. 11.7 +/-12.6sec, P<0.05) were significantly higher in VAO group. Six out of 50 patients(12%) had an increased titer of IgG-ACA and LA was found in 11 patients(22%). No patients were positive for ACA and LA simultaneously. There was no significant difference in sex, etiology of ESRD, diabetic status, the dosage of heparin during HD or the amount of erythropoietin administered according to the presence of APAs. We could not find any significant correlation between the titer of APAs and age, duration of dialysis, blood pressure, platelet count and biochemical parameters. In the patients with positive ACA, the frequency of VAO was 1.05+/-0.12 episodes/patient year, which was significantly higher than patients without ACA (0.33+/-0.17 episodes/ patient year, P<0.05). In the patients with the presence of LA(1.06+/-0.43 vs. 0.12+/-0.06 episodes/ patients year, P<0.01). The median vascular access survival time in IgG-ACA positive patients (32.7 months) was significantly decreased compared to 66.8 months in IgG-ACA negative group. CONCLUSION: Our data suggest that the presence of APAs (ACA and/or LA) affects the event-free vascular access survival in HD patients. Therefore the evaluation of APAs status have to be included in the diagnostic strategies for the patients with recurrent VAO. Further studies are necessary to explore the pharmacologic intervention method to decrease APAs and prevent VAO in HD patients.
Antibodies, Anticardiolipin*
;
Antibodies, Antiphospholipid
;
Arteriovenous Fistula
;
Blood Platelets
;
Blood Pressure
;
Dialysis
;
Enzyme-Linked Immunosorbent Assay
;
Erythropoietin
;
Heparin
;
Humans
;
Kidney Failure, Chronic
;
Lupus Coagulation Inhibitor*
;
Platelet Count
;
Renal Dialysis*
;
Retrospective Studies
;
Risk Factors
;
Thrombosis
9.Pulmonary hemorrhage in pediatric lupus anticoagulant hypoprothrombinemia syndrome.
Ji Soo KIM ; Min Jae KIM ; E Young BAE ; Dae Chul JEONG
Korean Journal of Pediatrics 2014;57(4):202-205
Lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS), a very rare disease that is caused by the presence of antifactor II antibodies, is usually counterbalanced by the prothrombotic effect of lupus anticoagulant (LAC). Patients with LAHPS are treated using fresh frozen plasma, steroids, immunosuppressive agents, and immunoglobulins for managing the disease and controlling hemorrhages. Notably, steroids are the important treatment for treating hypoprothrombinemia and controlling the bleeding. However, some patients suffer from severe, life-threatening hemorrhages, when factor II levels remain very low in spite of treatment with steroids. Here, we report a case of LAHPS in a 15-year-old girl who experienced pulmonary hemorrhage with rapid progression. She was referred to our hospital owing to easy bruising and prolonged bleeding. She was diagnosed with LAHPS that presented with pancytopenia, positive antinuclear antibody, proloned prothrombin time, activated partial thromboplastin time, positive LAC antibody, and factor II deficiency. Her treatment included massive blood transfusion, high-dose methylprednisolone, vitamin K, and immunoglobulin. However, she died due to uncontrolled pulmonary hemorrhage.
Adolescent
;
Antibodies
;
Antibodies, Antinuclear
;
Blood Transfusion
;
Female
;
Hemorrhage*
;
Humans
;
Hypoprothrombinemias*
;
Immunoglobulins
;
Immunosuppressive Agents
;
Lupus Coagulation Inhibitor*
;
Methylprednisolone
;
Pancytopenia
;
Partial Thromboplastin Time
;
Plasma
;
Prothrombin
;
Prothrombin Time
;
Rare Diseases
;
Steroids
;
Vitamin K
10.Etiologic characteristics and index pregnancy outcomes of recurrent pregnancy losses in Korean women.
Gi Su LEE ; Joon Cheol PARK ; Jeong Ho RHEE ; Jong In KIM
Obstetrics & Gynecology Science 2016;59(5):379-387
OBJECTIVE: The goal of this study was to evaluate the etiologies and clinical outcomes of Korean recurrent pregnancy loss (RPL) patients. And also, we investigated the differences between primary and secondary RPL patients, between two and three or more pregnancy losses. METHODS: One hundred seventy eight women diagnosed as RPL were enrolled. We performed chromosomal analysis, thyroid stimulating hormone, prolactin, blood glucose, plasminogen activator inhibitor-1, natural killer cell proportion, anticardiolipin antibodies, antiphospholipid antibodies, lupus anticoagulant, anti-β2glycoprotein-1 antibodies, antinuclear antibody, protein C, protein S, antithrombin III, homocysteine, MTFHR gene, factor V Leiden mutation, and hysterosalphingography/hysteroscopic evaluation. RESULTS: The mean age was 34.03±4.30 years, and mean number of miscarriages was 2.69±1.11 (range, 2 to 11). Anatomical cause (13.5%), chromosomal abnormalities (5.6%), and endocrine disorders (34.3%) were observed in RPL women. Elevated natural killer cell and antiphospholipid antibodies were observed in 43.3% and 7.3% each. Among of 178 women, 77 women were pregnant. After management of those women, live birth rate was 84.4% and mean gestational weeks was 37.63±5.12. Women with three or more RPL compared with women with two RPL had more common anatomical cause such as intrauterine adhesions and lower rates of spontaneous pregnancy. Compare with secondary RPL women, immunological abnormalities were more common in primary RPL. However, miscarriage rates were not different. CONCLUSION: Immunological factor including autoimmune and alloimmune disorders was most common etiology of RPL. Inherited thrombophilia showed different patterns with other ethnic countries. Miscarriage rates were not different between primary and secondary RPL, or between two and three or more miscarriages group.
Abortion, Spontaneous
;
Antibodies, Anticardiolipin
;
Antibodies, Antinuclear
;
Antibodies, Antiphospholipid
;
Antithrombin III
;
Blood Glucose
;
Chromosome Aberrations
;
Factor V
;
Female
;
Homocysteine
;
Humans
;
Killer Cells, Natural
;
Live Birth
;
Lupus Coagulation Inhibitor
;
Plasminogen Activators
;
Pregnancy
;
Pregnancy Outcome*
;
Pregnancy*
;
Prolactin
;
Protein C
;
Protein S
;
Thrombophilia
;
Thyrotropin